Treatment Sequencing Survival Model for Patients with Multiple Myeloma Ineligible for Stem Cell Transplantation (SCT)
Value Health
.
2014 Nov;17(7):A617-8.
doi: 10.1016/j.jval.2014.08.2182.
Epub 2014 Oct 26.
Authors
B Heeg
1
,
M Van Agthoven
2
,
C van Beurden-Tan
3
,
J Liwing
4
,
U H Mellqvist
5
,
T Plesner
6
,
F Logman
7
,
J Aschan
4
,
H Einsele
8
,
M Treur
1
,
M Barendse
4
,
P G Richardson
9
,
A Palumbo
10
,
H Nahi
11
,
P Sonneveld
3
Affiliations
1
Pharmerit International, Rotterdam, The Netherlands.
2
Janssen-Cilag BV, Tilburg, The Netherlands.
3
Erasmus University Medical Center, Rotterdam, The Netherlands.
4
Janssen-Cilag AB, Sollentuna, Sweden.
5
Department of Hematology, Gothenburg, Sweden.
6
Vejle Hospital, Vejle, Denmark.
7
Eastbridge Pharma BV, Utrecht, The Netherlands.
8
Medizinische Klinik II, Würzburg, Germany.
9
Dana-Farber Cancer Institute, Boston, MA, USA.
10
University of Torino, Torino, Italy.
11
Karolinska University Hospital, Solna, Sweden.
PMID:
27202167
DOI:
10.1016/j.jval.2014.08.2182
No abstract available